|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||65.265 - 65.834|
|52 Week Range||54.380 - 65.834|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.35%|
The specter of legislative action on drug prices has faded in the past year, but high costs are still very much a concern for the medical community. Now, the U.S.'s largest hospitals have announced they’re planning to create a nonprofit generic drug company in response to high prices and shortages of some medical products. Leerink's Ami Fadia writes that the news is more evidence of an "increasingly competitive environment" in health care, especially for products that have limited competition, as the Food and Drug Administration has already emphasized accelerating its review process.
While most of the sectors would benefit from Trump's plan, some are set to explode higher than others due to their highest effective tax rate.
Stocks in the sector have staged an impressive comeback this year, with biotechs leading the charge.
House Republicans have released the long-awaited bill to repeal and replace Obama's signature healthcare law last evening. This will unwind much of the law over the next three years.
The President is expected to bring more clarity on promised tax cuts, big spending, and other business friendly policies in his first speech to Congress slated to be held later today.